- Home
- SHPH vs PSTV Comparison
SHPH vs PSTV Comparison
Compare SHPH & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- PSTV
- Stock Information
- Founded
- SHPH 2012
- PSTV 1996
- Country
- SHPH United States
- PSTV United States
- Employees
- SHPH N/A
- PSTV N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- SHPH Health Care
- PSTV Health Care
- Exchange
- SHPH Nasdaq
- PSTV Nasdaq
- Market Cap
- SHPH 2.2M
- PSTV 2.1M
- IPO Year
- SHPH 2022
- PSTV N/A
- Fundamental
- Price
- SHPH $0.41
- PSTV $1.01
- Analyst Decision
- SHPH
- PSTV Strong Buy
- Analyst Count
- SHPH 0
- PSTV 3
- Target Price
- SHPH N/A
- PSTV $11.17
- AVG Volume (30 Days)
- SHPH 257.5K
- PSTV 47.0M
- Earning Date
- SHPH 05-12-2025
- PSTV 03-27-2025
- Dividend Yield
- SHPH N/A
- PSTV N/A
- EPS Growth
- SHPH N/A
- PSTV N/A
- EPS
- SHPH N/A
- PSTV N/A
- Revenue
- SHPH N/A
- PSTV $5,824,000.00
- Revenue This Year
- SHPH N/A
- PSTV N/A
- Revenue Next Year
- SHPH N/A
- PSTV N/A
- P/E Ratio
- SHPH N/A
- PSTV N/A
- Revenue Growth
- SHPH N/A
- PSTV 18.54
- 52 Week Low
- SHPH $0.33
- PSTV $0.24
- 52 Week High
- SHPH $4.71
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- SHPH 33.79
- PSTV 49.15
- Support Level
- SHPH $0.35
- PSTV $0.94
- Resistance Level
- SHPH $0.41
- PSTV $1.77
- Average True Range (ATR)
- SHPH 0.05
- PSTV 0.32
- MACD
- SHPH 0.01
- PSTV 0.01
- Stochastic Oscillator
- SHPH 33.96
- PSTV 34.91
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).